Modality
Gene Editing
MOA
TNFi
Target
CD19
Pathway
T-cell
EoE
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
Feb 2021
→ Feb 2028
Phase 3Current
NCT03622671
2,639 pts·EoE
2021-02→2028-02·Completed
2,639 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-161.9y awayPh3 Readout· EoE
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Complet…
Catalysts
Ph3 Readout
2028-02-16 · 1.9y away
EoE
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03622671 | Phase 3 | EoE | Completed | 2639 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Rimatinib | Ventyx Bio | Phase 1 | CD20 |